Literature DB >> 25041869

Effects of factor Xa on the expression of proteins in femoral arteries from type 2 diabetic patients.

Antonio J López-Farré1, Pablo Rodriguez-Sierra, Javier Modrego, Antonio Segura, Naiara Martín-Palacios, Ana M Saiz, José J Zamorano-León, Juan Duarte, Javier Serrano, Guillermo Moñux.   

Abstract

AIM: Further to its pivotal role in haemostasis, factor Xa (FXa) promotes effects on the vascular wall. The purpose of the study was to evaluate if FXa modifies the expression level of energy metabolism and oxidative stress-related proteins in femoral arteries obtained from type 2 diabetic patients with end-stage vasculopathy.
METHODS: Femoral arteries were obtained from 12 type 2 diabetic patients who underwent leg amputation. Segments from the femoral arteries were incubated in vitro alone and in the presence of 25 nmol l(-1) FXa and 25 nmol l(-1) FXa + 50 nmol l(-1) rivaroxaban.
RESULTS: In the femoral arteries, FXa increased triosephosphate isomerase and glyceraldehyde-3-phosphate dehydrogenase isotype 1 expression but decreased pyruvate dehydrogenase expression. These facts were accompanied by an increased content of acetyl-CoA. Aconitase activity was reduced in FXa-incubated femoral arteries as compared with control. Moreover, FXa increased the protein expression level of oxidative stress-related proteins which was accompanied by an increased malonyldialdehyde arterial content. The FXa inhibitor, rivaroxaban, failed to prevent the reduced expression of pyruvate dehydrogenase induced by FXa but reduced acetyl-CoA content and reverted the decreased aconitase activity observed with FXa alone. Rivaroxaban + FXa but not FXa alone increased the expression level of carnitine palmitoyltransferase I and II, two mitochondrial long chain fatty acid transporters. Rivaroxaban also prevented the increased expression of oxidative stress-related proteins induced by FXa alone.
CONCLUSIONS: In femoral isolated arteries from type 2 diabetic patients with end-stage vasculopathy, FXa promoted disruption of the aerobic mitochondrial metabolism. Rivaroxaban prevented such effects and even seemed to favour long chain fatty acid transport into mitochondria.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  energy metabolism; factor Xa; femoral arteries; oxidative stress; protein expression

Mesh:

Substances:

Year:  2014        PMID: 25041869      PMCID: PMC4256625          DOI: 10.1111/bcp.12469

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  46 in total

1.  Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism.

Authors:  M Steinhoff; N Vergnolle; S H Young; M Tognetto; S Amadesi; H S Ennes; M Trevisani; M D Hollenberg; J L Wallace; G H Caughey; S E Mitchell; L M Williams; P Geppetti; E A Mayer; N W Bunnett
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

Review 2.  Diabetes and cardiovascular disease.

Authors:  J R Sowers; M A Lester
Journal:  Diabetes Care       Date:  1999-04       Impact factor: 19.112

3.  Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.

Authors: 
Journal:  Diabet Med       Date:  2006-06       Impact factor: 4.359

4.  Coagulation factor Xa induces endothelium-dependent relaxations in rat aorta.

Authors:  P Schaeffer; A M Mares; F Dol; F Bono; J M Herbert
Journal:  Circ Res       Date:  1997-11       Impact factor: 17.367

Review 5.  Free fatty acids, insulin resistance, and type 2 diabetes mellitus.

Authors:  G Boden
Journal:  Proc Assoc Am Physicians       Date:  1999 May-Jun

6.  Study on total antioxidant status in relation to oxidative stress in type 2 diabetes mellitus.

Authors:  A Jamuna Rani; S V Mythili
Journal:  J Clin Diagn Res       Date:  2014-03-15

7.  Coagulation activation is associated with nicotinamide adenine dinucleotide phosphate oxidase-dependent reactive oxygen species generation in hemodialysis patients.

Authors:  Marica Cariello; Simona Simone; Antonia Loverre; Margherita Gigante; Francesca Incampo; Stefania Pietanza; Mario Colucci; Francesco P Schena; Loreto Gesualdo; Giuseppe Grandaliano; Giovanni Pertosa
Journal:  Antioxid Redox Signal       Date:  2011-12-22       Impact factor: 8.401

8.  Expression of cytoskeleton and energetic metabolism-related proteins at human abdominal aortic aneurysm sites.

Authors:  Javier Modrego; Antonio J López-Farré; Isaac Martínez-López; Miguel Muela; Carlos Macaya; Javier Serrano; Guillermo Moñux
Journal:  J Vasc Surg       Date:  2012-01-04       Impact factor: 4.268

9.  The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus.

Authors:  A Ceriello; A Quatraro; E Marchi; M Barbanti; P Dello Russo; P Lefebvre; D Giugliano
Journal:  Diabet Med       Date:  1990-05       Impact factor: 4.359

10.  Proteomic analysis of plasma from patients during an acute coronary syndrome.

Authors:  Petra J Mateos-Cáceres; Antonio García-Méndez; Antonio López Farré; Carlos Macaya; Antonio Núñez; Juan Gómez; Sergio Alonso-Orgaz; Carolina Carrasco; Marta Escribano Burgos; Raimundo de Andrés; Juan J Granizo; Jerónimo Farré; Luis A Rico
Journal:  J Am Coll Cardiol       Date:  2004-10-19       Impact factor: 24.094

View more
  2 in total

1.  FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms.

Authors:  Guillermo Moñux; Jose J Zamorano-León; Pablo Marqués; Bernardo Sopeña; J M García-García; G Laich de Koller; Bibiana Calvo-Rico; Miguel A García-Fernandez; J Serrano; Antonio López-Farré
Journal:  Br J Clin Pharmacol       Date:  2017-08-27       Impact factor: 4.335

2.  Effects of Oral Anticoagulant Therapy on Gene Expression in Crosstalk between Osteogenic Progenitor Cells and Endothelial Cells.

Authors:  Luca Dalle Carbonare; Monica Mottes; Anna Brunelli; Michela Deiana; Samuele Cheri; Silvia Suardi; Maria Teresa Valenti
Journal:  J Clin Med       Date:  2019-03-08       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.